Pharming Group NV, a specialty pharmaceutical company headquartered in Leiden, Netherlands, operates within the biotechnology sector of the health care industry. The company is listed on the NYSE Euronext Amsterdam and trades in euros (EUR). As of December 30, 2025, Pharming Group NV’s close price was recorded at 1.434 EUR, with a 52-week high of 1.51 EUR on November 25, 2025, and a 52-week low of 0.6555 EUR on April 6, 2025. The company’s market capitalization stands at 977,020,000 EUR, and it has a notably high price-to-earnings ratio of 86,550.
Pharming Group NV is renowned for its development and production of human therapeutic proteins aimed at addressing rare diseases and unmet medical needs. The company’s flagship product, Ruconest, is a recombinant human C1 esterase inhibitor used to treat angioedema attacks in patients with acute hereditary angioedema (HAE). Ruconest is available in several regions, including Europe, the United States, Israel, European Union countries, Norway, Iceland, and Liechtenstein.
In addition to Ruconest, Pharming Group NV is actively engaged in the development of other recombinant proteins. These include a recombinant human C1 inhibitor for treating HAE attacks and recombinant human factor VIII (rhFVIII), a natural human blood clotting factor intended for the treatment of haemophilia A. These efforts underscore the company’s commitment to expanding its therapeutic offerings for rare diseases.
Strategic collaborations play a crucial role in Pharming Group NV’s growth strategy. The company has established partnerships with the Shanghai Institute of Pharmaceutical Industry and the China State Institute of Pharmaceutical Industry. These collaborations focus on the development, manufacture, and commercialization of new products leveraging Pharming’s proprietary technology platform. Specifically, the partnership with the China State Institute of Pharmaceutical Industry is centered on the development of rhFVIII for haemophilia A treatment.
On the last trading day of 2025, the Dutch market experienced a modest uptick, with the AEX index registering a small gain. However, Pharming Group NV saw a modest decline in its stock price, reflecting a broader cautious sentiment among investors. Despite this, the company’s focus remains on long-term growth, driven by its pipeline development and strategic partnerships.
Investors are closely monitoring regulatory updates and partnership milestones, which are expected to significantly impact Pharming Group NV’s future performance. The company’s ongoing efforts to expand its product pipeline and manufacturing capabilities through strategic collaborations suggest a robust strategy aimed at sustaining growth in the specialty pharmaceutical sector.
